There is a surge in the implied volatility for the stock options of Alnylam Pharmaceuticals. Despite the massive share price surge in 2025, experts continue to debate if it's too late to invest in the company. Notably, Gilder Gagnon Howe & Co. LLC has sold 8,487 shares of the pharmaceutical firm. Alnylam and Seagate are to join the NASDAQ 100, with Lululemon and Biogen exiting. The company's stock demonstrates resilience against downside risks and manages to maintain an optimistic revenue outlook. In addition, it has announced the partial repurchase of its convertible senior notes due in 2027. The company's successful strategies and groundbreaking research, particularly ALNY’s science chief's contributions to RNAi which once looked doomed, has also raised questions regarding its potential to generate significant wealth for its investors. Alnylam's successful financial performances, such as raising their stock price target to $508 and reporting $492M Amvuttra sales, also make investing in their company a promising endeavor. With the recent developments revolving around Alnylam, the company's stock surge of 73.9% is justified.
Alnylam Pharmaceuticals News Analytics from Thu, 24 Jul 2025 07:00:00 GMT to Sat, 13 Dec 2025 13:57:57 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 4
